Sign in
CompletedNo phase

Clinical Pharmacist-Led Cardiovascular Risk Assessment in Patients With Chronic Kidney Disease (CRICKD)

Key facts

Who runs it
Marmara University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
150 people enrolled
Started
3 Jan 2022
Ended
15 Mar 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Clinical Pharmacist-Led Pharmaceutical Care
  • Standard Medical Care (SMC)
Record updated
12 November 2026

Who can take part

Age
18 years to 74 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adults aged 18-74 years
  • Patients diagnosed with chronic kidney disease (CKD), including those receiving dialysis
  • Patients hospitalised in the internal medicine clinic
  • Patients who agreed to participate in the study

Who cannot take part

  • Patients with dementia or Alzheimer's disease
  • Patients who did not agree to participate in the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Chronic kidney disease (CKD) is a long-term condition that can increase the risk of cardiovascular diseases, such as heart attacks and strokes. People with CKD often have other health conditions and take several medications, which can make following treatment plans challenging. Clinical pharmacists may help these patients by reviewing their medications, providing education, and supporting medication adherence and cardiovascular risk management.

Read full original descriptionShow less

This study evaluated the impact of a clinical pharmacist-led pharmaceutical care program on cardiovascular risk, medication adherence, and quality of life in hospitalized adults with CKD.

The study was conducted at a research and training hospital in Istanbul, Türkiye, with a planned six-month follow-up. A total of 150 patients were initially enrolled and assigned to either an intervention group or a control group. Due to deaths, withdrawal from the study, and loss to follow-up, 101 patients were included in the final analysis.

Patients in the control group received standard medical care. Patients in the intervention group received additional pharmaceutical care from a clinical pharmacist, including medication review, education about CKD and cardiovascular risk factors, counseling on medication adherence and lifestyle changes, and follow-up counseling.

The study assessed cardiovascular risk using a Framingham-based risk model. Medication adherence and health-related quality of life were evaluated using standardized questionnaires. Medication regimen complexity and relevant clinical measurements were also assessed.

The findings showed that cardiovascular risk scores decreased in both groups during the study period. Medication adherence increased in both groups, from 59.2% to 75.5% in the control group and from 75.0% to 88.5% in the intervention group. However, the difference in medication adherence between the groups at follow-up was not statistically significant. Quality-of-life scores were significantly higher in the intervention group at both baseline and follow-up. A weak negative correlation was observed between medication regimen complexity and quality of life, indicating that greater medication complexity was associated with lower quality-of-life scores.

Overall, the findings suggest that clinical pharmacist-led pharmaceutical care may support medication management in patients with CKD. However, the study did not demonstrate statistically significant differences between groups in medication adherence or cardiovascular risk outcomes. Further studies with larger samples and adequate follow-up are needed to clarify the effects of pharmacist-led interventions in this population.

The 2 groups in the trial

  • Clinical Pharmacist-Led Pharmaceutical CareTreatment being tested

    Participants in this group received standard medical care in addition to a clinical pharmacist-led pharmaceutical care program. The intervention included medication review, education about chronic kidney disease and cardiovascular risk factors, counselling on medication adherence, and advice on lifestyle modifications, including dietary recommendations and smoking cessation. Follow-up counselling was provided during the six-month study period.

  • Standard Medical Care (Control Group)Treatment being tested

    Participants in this group received standard medical care without the additional clinical pharmacist-led pharmaceutical care programme.

    Treatment: Standard Medical Care (SMC)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Clinical Pharmacist-Led Cardiovascular Risk Assessment on Medication Adherence and Quality of Life in Patients With Chronic Kidney Disease: A Randomised Controlled Study
Record updated
12 November 2026